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Comment on: Risk Factors for Heart Failure in Patients with Type 2 Diabetes Mellitus
and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
To the Editor:
We read with great interest the article entitled, “Risk factors for Heart Failure in Patients with
Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone
Methyl” by Chin et al [1] in a recent issue of Journal of Cardiac Failure. The authors
reported that patients treated with bardoxolone methyl in the BEACON Phase III human
clinical trial with a baseline B-type natriuretic peptide (BNP) ≥200 pg/ml or prior
hospitalisation had a 60% increased risk of heart failure compared to the placebo group. We
believe that this information is crucial in order to design successful human clinical trials
investigating the potential benefits of bardoxolone methyl in the future. However, we have
some additional comments regarding the outcome of the study.
Firstly, the baseline BNP data in the classification trees for a) Figure 1: Classification tree for
heart failure events in BEACON and b) Figure 2: Classification tree for fluid overload or
heart failure events are set to a different level for the bardoxolone methyl group compared to
the control group (bardoxolone methyl = ± 183.pg/ml, placebo= ± 229.5pg/ml). Furthermore,
a study by Wang et al., reported that BNP levels as low as 20 pg/ml can increase the risk of
heart failure [2]. In addition, the conventional values for diagnosis of heart failure are usually
between 80 and 100 pg/ml [3, 4]. Therefore, an equal comparison between baseline BNP
levels and both the bardoxolone methyl and placebo group in the BEACON clinical trial is
necessary. A consideration of the risk of heart failure in patients treated with bardoxolone
methyl compared to placebo with lower BNP levels would also be interesting to consider in
future studies.
Secondly, there is controversy surrounding the usefulness of BNP as a biomarker for heart
failure mechanisms, since levels vary widely in the general population based on factors
including age, gender and BMI [5, 6]. Specifically, elevated BNP levels can occur in
conditions independent of heart failure including old age, the use of hormone replacement
therapy, and obesity [7]. In this study, patients had type 2 diabetes and stage 4 chronic kidney
disease and were divided only into a bardoxolone methyl treatment or placebo group, and
were not divided according to other parameters such as age, gender and BMI. Therefore,
whether there were differences between these factors in the BEACON trial may also be
interesting parameters to investigate to eliminate potential non heart failure mechanisms that
have the ability to elevate BNP levels.
In conclusion, despite the risk factors for heart failure identified in this study, the benefits of
bardoxolone methyl in earlier human clinical trials and preclinical animal studies cannot be
ignored [8]. Future studies should focus on identifying molecular mechanisms in the heart
and the cardiovascular network that explain potential increased risks of the development of
heart failure in patients treated with bardoxolone methyl [9]. This will allow the development
of more robust human clinical trials using bardoxolone methyl in the future.
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